JP2016502997A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502997A5 JP2016502997A5 JP2015547078A JP2015547078A JP2016502997A5 JP 2016502997 A5 JP2016502997 A5 JP 2016502997A5 JP 2015547078 A JP2015547078 A JP 2015547078A JP 2015547078 A JP2015547078 A JP 2015547078A JP 2016502997 A5 JP2016502997 A5 JP 2016502997A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- composition
- use according
- vaccine
- monoglycerides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 claims 11
- 150000001735 carboxylic acids Chemical class 0.000 claims 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 7
- 239000005642 Oleic acid Substances 0.000 claims 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 6
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 6
- 206010061598 Immunodeficiency Diseases 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 4
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims 4
- 239000005639 Lauric acid Substances 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims 3
- 229960002733 gamolenic acid Drugs 0.000 claims 3
- 125000005456 glyceride group Chemical group 0.000 claims 3
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 claims 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims 2
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims 2
- 235000021353 Lignoceric acid Nutrition 0.000 claims 2
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 2
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 2
- 235000021355 Stearic acid Nutrition 0.000 claims 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 2
- 235000021342 arachidonic acid Nutrition 0.000 claims 2
- 229940114079 arachidonic acid Drugs 0.000 claims 2
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims 2
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 claims 2
- HABLENUWIZGESP-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O HABLENUWIZGESP-UHFFFAOYSA-N 0.000 claims 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims 2
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 235000020778 linoleic acid Nutrition 0.000 claims 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 2
- 229960004488 linolenic acid Drugs 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 2
- 229960002446 octanoic acid Drugs 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000008117 stearic acid Substances 0.000 claims 2
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 235000021357 Behenic acid Nutrition 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 229940116226 behenic acid Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 1
- 230000007485 viral shedding Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12197522.1A EP2742952A1 (en) | 2012-12-17 | 2012-12-17 | Influenza vaccine composition |
| EP12197522.1 | 2012-12-17 | ||
| PCT/EP2013/077007 WO2014095944A1 (en) | 2012-12-17 | 2013-12-17 | Vaccine composition for use in immuno-compromised populations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502997A JP2016502997A (ja) | 2016-02-01 |
| JP2016502997A5 true JP2016502997A5 (OSRAM) | 2016-12-01 |
Family
ID=47358019
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547078A Pending JP2016502997A (ja) | 2012-12-17 | 2013-12-17 | 免疫無防備状態の集団において使用するためのワクチン組成物 |
| JP2015547077A Pending JP2016502996A (ja) | 2012-12-17 | 2013-12-17 | ナイーブな対象のためのワクチン組成物 |
| JP2019049330A Pending JP2019112448A (ja) | 2012-12-17 | 2019-03-18 | ナイーブな対象のためのワクチン組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547077A Pending JP2016502996A (ja) | 2012-12-17 | 2013-12-17 | ナイーブな対象のためのワクチン組成物 |
| JP2019049330A Pending JP2019112448A (ja) | 2012-12-17 | 2019-03-18 | ナイーブな対象のためのワクチン組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20150306204A1 (OSRAM) |
| EP (4) | EP2742952A1 (OSRAM) |
| JP (3) | JP2016502997A (OSRAM) |
| KR (3) | KR20210007042A (OSRAM) |
| CN (3) | CN112826929A (OSRAM) |
| AU (2) | AU2013360889C1 (OSRAM) |
| BR (2) | BR112015014174A2 (OSRAM) |
| CA (2) | CA2895028A1 (OSRAM) |
| HK (2) | HK1212611A1 (OSRAM) |
| MX (2) | MX2015007753A (OSRAM) |
| RU (2) | RU2661408C2 (OSRAM) |
| WO (2) | WO2014095943A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103298484B (zh) * | 2010-09-30 | 2017-04-26 | 优若森疫苗公司 | 改进的疫苗组合物 |
| EP4144369A1 (en) * | 2014-09-26 | 2023-03-08 | Seqirus UK Limited | Vaccination of immunocompromised subjects |
| JP2017528511A (ja) | 2014-09-26 | 2017-09-28 | セキラス ユーケー リミテッド | 免疫低下された被験体のワクチン接種 |
| RU2634247C2 (ru) * | 2015-09-28 | 2017-10-24 | Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) | Способ стимуляции иммунного ответа и препарат для его осуществления |
| US20200306364A1 (en) * | 2017-11-30 | 2020-10-01 | Ohio State Innovation Foundation | Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system |
| EP4135519B1 (en) * | 2020-04-16 | 2024-09-25 | Bayer Aktiengesellschaft | Active compound combinations and fungicide compositions comprising those |
| US20230133087A1 (en) * | 2020-04-16 | 2023-05-04 | Bayer Aktiengesellschaft | Active compound combinations and fungicide compositions comprising those |
| WO2021209364A1 (en) * | 2020-04-16 | 2021-10-21 | Bayer Aktiengesellschaft | Active compound combinations and fungicide compositions comprising those |
| CN112063699B (zh) * | 2020-09-16 | 2021-06-18 | 成都市疾病预防控制中心 | 一种用于研究hiv感染者免疫衰老机制的系统 |
| WO2023133342A2 (en) * | 2022-01-10 | 2023-07-13 | The Children's Medical Center Corporation | Methods and compositions relating to immunization of immune distinct patients |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9602280D0 (sv) | 1996-06-10 | 1996-06-10 | Pharmatrix Ab | Immunstimulerande lipidformulering |
| SE9900496D0 (sv) | 1999-02-12 | 1999-02-12 | Pharmatrix Ab | Vaccine formulation |
| US8410248B2 (en) | 1999-03-12 | 2013-04-02 | Human Genome Sciences Inc. | HWBAO62 polypeptides |
| JP2004527524A (ja) | 2001-04-05 | 2004-09-09 | カイロン コーポレイション | 非経口初回抗原刺激後の粘膜追加免疫 |
| US20050208602A1 (en) | 2001-08-10 | 2005-09-22 | Rosen Craig A | 89 human secreted proteins |
| WO2004042000A2 (en) | 2002-05-17 | 2004-05-21 | Human Genome Sciences, Inc. | 157 human secreted proteins |
| DK1567191T3 (da) | 2002-11-26 | 2011-01-03 | Eurocine Vaccines Ab | Ny amin-baseret adjuvans |
| CN1867355A (zh) | 2003-08-11 | 2006-11-22 | 财团法人阪大微生物病研究会 | 包含诱导粘膜免疫的佐剂的新型疫苗 |
| WO2006125076A2 (en) | 2005-05-18 | 2006-11-23 | Trinity Biosystems, Inc. | Methods and compositions for immunizing against chlamydia infection |
| KR101294455B1 (ko) | 2005-06-30 | 2013-08-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 면역 아쥬반트 제조용 화합물 |
| US8211442B2 (en) | 2005-08-05 | 2012-07-03 | The University Of Tokushima | Mucosal vaccine enabling switching from production of IgA antibody to production of both of IgA and IgG antibodies |
| RU2323742C1 (ru) * | 2007-02-15 | 2008-05-10 | Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) | Способ повышения иммуногенности инактивированной гриппозной вакцины |
| EP2227251A1 (en) * | 2007-12-06 | 2010-09-15 | GlaxoSmithKline Biologicals SA | Influenza composition |
| CA2725381A1 (en) | 2008-05-23 | 2010-03-25 | The Regents Of The University Of Michigan | Nanoemulsion adjuvants |
| US9415006B2 (en) | 2008-05-23 | 2016-08-16 | The Regents Of The University Of Michigan | Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same |
| US20130178383A1 (en) | 2008-11-12 | 2013-07-11 | David Spetzler | Vesicle isolation methods |
| ES2618576T3 (es) | 2009-05-28 | 2017-06-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico |
| CN103298484B (zh) | 2010-09-30 | 2017-04-26 | 优若森疫苗公司 | 改进的疫苗组合物 |
-
2012
- 2012-12-17 EP EP12197522.1A patent/EP2742952A1/en not_active Withdrawn
-
2013
- 2013-12-17 RU RU2015129077A patent/RU2661408C2/ru not_active IP Right Cessation
- 2013-12-17 EP EP13805935.7A patent/EP2931307B1/en not_active Not-in-force
- 2013-12-17 US US14/650,807 patent/US20150306204A1/en not_active Abandoned
- 2013-12-17 EP EP13811462.4A patent/EP2931308B1/en not_active Not-in-force
- 2013-12-17 WO PCT/EP2013/077006 patent/WO2014095943A1/en not_active Ceased
- 2013-12-17 JP JP2015547078A patent/JP2016502997A/ja active Pending
- 2013-12-17 HK HK16100580.8A patent/HK1212611A1/zh unknown
- 2013-12-17 CA CA2895028A patent/CA2895028A1/en not_active Abandoned
- 2013-12-17 EP EP18193418.3A patent/EP3431101A1/en not_active Withdrawn
- 2013-12-17 CN CN202110039199.9A patent/CN112826929A/zh active Pending
- 2013-12-17 MX MX2015007753A patent/MX2015007753A/es unknown
- 2013-12-17 KR KR1020217000812A patent/KR20210007042A/ko not_active Ceased
- 2013-12-17 AU AU2013360889A patent/AU2013360889C1/en not_active Ceased
- 2013-12-17 AU AU2013360890A patent/AU2013360890B2/en not_active Ceased
- 2013-12-17 RU RU2015129028A patent/RU2661407C2/ru not_active IP Right Cessation
- 2013-12-17 WO PCT/EP2013/077007 patent/WO2014095944A1/en not_active Ceased
- 2013-12-17 CN CN201380065856.0A patent/CN104884085A/zh active Pending
- 2013-12-17 MX MX2015007688A patent/MX2015007688A/es unknown
- 2013-12-17 HK HK16101591.3A patent/HK1213492A1/zh unknown
- 2013-12-17 KR KR1020157019558A patent/KR20150132092A/ko not_active Ceased
- 2013-12-17 CA CA2895023A patent/CA2895023A1/en not_active Abandoned
- 2013-12-17 BR BR112015014174A patent/BR112015014174A2/pt not_active Application Discontinuation
- 2013-12-17 JP JP2015547077A patent/JP2016502996A/ja active Pending
- 2013-12-17 CN CN201380065877.2A patent/CN104870010A/zh active Pending
- 2013-12-17 KR KR1020157019562A patent/KR20150132093A/ko not_active Ceased
- 2013-12-17 BR BR112015014243A patent/BR112015014243A8/pt not_active Application Discontinuation
- 2013-12-17 US US14/650,809 patent/US11065325B2/en not_active Expired - Fee Related
-
2019
- 2019-03-18 JP JP2019049330A patent/JP2019112448A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502997A5 (OSRAM) | ||
| JP2016502996A5 (OSRAM) | ||
| RU2015129077A (ru) | Вакцинная композиция для применения в популяциях субъектов с ослабленным иммунитетом | |
| CY1122248T1 (el) | Μιγμα λιπαρων οξεων προς χρηση στη θεραπευτικη αγωγη φλεγμονωδων παθολογιων | |
| EP3661600A4 (en) | FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME | |
| ZA201702385B (en) | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states | |
| JP2017523230A5 (OSRAM) | ||
| PH12015502517B1 (en) | Compositions and methods for nutrient delivery | |
| AR095335A1 (es) | Método para reducción del riesgo de enfermedad autoinmune | |
| JP2020182497A5 (OSRAM) | ||
| RU2013120034A (ru) | Усовершенствованные композиции вакцин | |
| JP2016060725A5 (OSRAM) | ||
| JP2017109944A5 (OSRAM) | ||
| Dudanova et al. | Nuclear receptor agonists in the treatment of nonalcoholic fatty liver disease | |
| Bianucci et al. | Origins of malaria and leishmaniasis in Sardinia: first results of a paleoimmunological study | |
| Chan et al. | Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares-Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for Chronic Hepatitis B (CHB): 241 | |
| Woods et al. | Serine glycine one-carbon metabolism drives effector responses to influenza infection in macrophages | |
| Seth et al. | Ml Polarization bias and subsequent NASH progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1 induced oxidative stress: 1160 | |
| Xiaoqin | Battling Cancer | |
| Kulikova et al. | Experimental model of the primary male hypogonadism | |
| Goodwin et al. | Mesenchymal Stem Cells Abrogate Allergic Airways Disease By Presenting Antigen To CD4 Lymphocytes And Promoting A Th1 Phenotype | |
| Ma et al. | Hantaan Virus Infection Induces both Th1 and ThCTL Immune responses that Associated with the Viral Control and Clinical Outcome in Humans | |
| Nordgren et al. | C22 AIRWAY REPAIR AND RESOLUTION MECHANISMS: The Omega-3 Fatty Acid Docosahexaenoic Acid Attenuates Lung Inflammation Induced By Agricultural Dust Exposure | |
| Csak et al. | INFLAMMASOME ACTIVATION OCCURS IN NONALCOHOLIC STEATOHEPATITIS IN VIVO AND IT IS MEDIATED BY FATTY ACIDS THROUGH SENSITIZATION TO LPS-INDUCED INFLAMMASOME ACTIVATION IN HEPATOCYTES: 61 | |
| Bravo-Naranjo | Chundu or pusana mala: Case report of a possible non recognized culture-bound syndrome |